Advanced in Cholangiocarcinoma (Bile Duct Cancer)

Tomoya Yokota

Shizuoka, JP 
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Shizuoka, JP 
OverviewLocationsClinical Research

Overview

Tomoya Yokota practices in Shizuoka, Japan. Mr. Yokota is rated as an Advanced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Cancer, Stomach Cancer, Gastrostomy, and Endoscopy.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Gender
Male

Locations

Shizuoka, Japan
Other Locations
Kobe, Japan
Department Of Head And Neck Medical Oncology, 1007 Shimonagakubo, Nagaizumi, Sunto Gun, Shimonagakubo, 4118777, Japan
Inage, 2638522, Japan
Kashiwa, Japan
Kawahara, 6068507, Japan
Nagoya, 4648681, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

126 Total Publications

Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yokota's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile